卡瑞利珠单抗联合化疗一线治疗晚期非鳞状非小细胞肺癌的成本效果分析  

Cost-effectiveness analysis of camrelizumab combined with chemotherapy in firstline treatment of advanced non-squamous non-small cell lung cancer

作　　者：胥昕怡 占美[2] 何治尧 陈晨 王凌[1] 徐珽[1,2] XU Xin-yi;ZHAN Mei;HE Zhi-yao;CHEN Chen;WANG Ling;XU Ting(West China School of Pharmacy,Sichuan University,Chengdu SICHUAN 610041,China;Department of Pharmacy,West China Hospital,Sichuan University,Chengdu SICHUAN 610041,China)

机构地区：[1]四川大学华西药学院,四川成都610041 [2]四川大学华西医院药剂科,四川成都610041

出　　处：《中国新药与临床杂志》2022年第10期617-621,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：北京医卫健康公益基金会项目(YWJKJJHKYJJ-PD2021003);国家重点研发计划课题(2020YFC2008302)。

摘　　要：目的 评价卡瑞利珠单抗联合化疗对比单纯化疗一线治疗晚期非鳞状非小细胞肺癌(NSCLC)的成本效果。方法 生存数据主要来源于CameL临床试验,根据NSCLC的3种健康状态模拟建立分区生存模型,对卡瑞利珠单抗联合化疗治疗方案(卡瑞利珠单抗组)和单纯化疗治疗方案(化疗组)进行成本效果分析,并采用敏感性分析探索关键参数对结果的影响。结果 与化疗组相比,卡瑞利珠单抗组效果增加了0.19 QALYs,成本却减少75 981.43元,增量成本效果比(ICER)为-402 785.13元·QALY^(-1)。敏感性分析结果均证明了该结果的稳健性。结论 与单纯化疗相比,卡瑞利珠单抗联合化疗一线治疗晚期非鳞状NSCLC具有成本效果优势。AIM To evaluate the cost-effectiveness of camrelizumab combined with chemotherapy and chemotherapy alone in the first-line treatment of advanced non-squamous non-small cell lung cancer( NSCLC). METHODS The survival data were mainly derived from the CameL clinical trial. A partitioned survival model was established according to the simulation of three health states of NSCLC, and the cost-effectiveness analysis of camrelizumab combined chemotherapy treatment regime(camrelizumab group) and chemotherapy alone treatment regime(chemotherapy group) was carried out. The sensitivity analysis was utilized to explore the impact of key parameters on the results. RESULTS Compared with the chemotherapy group, the cost of the camrelizumab group decreased by 75 981.43 yuan, but increased effectiveness of 0.19 QALYs. The incremental cost-effectiveness ratio( ICER) was-402 785.13 yuan per QALY. The sensitivity analysis results proved the stability of the results. CONCLUSION Compared with chemotherapy alone, camrelizumab combined with chemotherapy is cost-effective in the first-line treatment of advanced non-squamous NSCLC.

关 键 词：卡瑞利珠单抗 癌 非小细胞肺 成本效用分析 分区生存模型 

分 类 号：R956[医药卫生—药学] R979.1